The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified fusion polypeptides. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Genetically modified fusion polypeptides is a key innovation area in drug development

A recombinant fusion protein is made by genetically engineering a fusion gene. Fusion genes may occur naturally in the body by the transfer of DNA between chromosomes or can be made in the laboratory by combining genes or parts of genes from the same or different organisms to treat diseases.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 190+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically modified fusion polypeptides.

Key players in genetically modified fusion polypeptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to genetically modified fusion polypeptides

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Bristol-Myers Squibb 620 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 379 Unlock Company Profile
Cellectis 326 Unlock Company Profile
Gilead Sciences 301 Unlock Company Profile
bluebird bio 225 Unlock Company Profile
Autolus 221 Unlock Company Profile
Eureka Therapeutics 208 Unlock Company Profile
City of Hope 201 Unlock Company Profile
Fred Hutchinson Cancer Research Center 183 Unlock Company Profile
Miltenyi Biotec 153 Unlock Company Profile
CARsgen Therapeutics 139 Unlock Company Profile
CRISPR Therapeutics 121 Unlock Company Profile
Seattle Children's Hospital 120 Unlock Company Profile
TCR2 Therapeutics 115 Unlock Company Profile
ImmunityBio 109 Unlock Company Profile
Pfizer 102 Unlock Company Profile
Aleta Biotherapeutics 100 Unlock Company Profile
Alpine Immune Sciences 86 Unlock Company Profile
Precision Biosciences 81 Unlock Company Profile
Amgen 77 Unlock Company Profile
Innovative Cellular Therapeutics 76 Unlock Company Profile
Massachusetts General Hospital 65 Unlock Company Profile
Nanjing Legend Biotech 64 Unlock Company Profile
Fate Therapeutics 62 Unlock Company Profile
BioNTech 60 Unlock Company Profile
iCell Gene Therapeutics 59 Unlock Company Profile
Allogene Therapeutics 56 Unlock Company Profile
Regeneron Pharmaceuticals 55 Unlock Company Profile
United States Of America 54 Unlock Company Profile
Sangamo Therapeutics 53 Unlock Company Profile
PT Soho Global Health Tbk 50 Unlock Company Profile
CytoImmune Therapeutics 48 Unlock Company Profile
Johnson & Johnson 44 Unlock Company Profile
Precigen 44 Unlock Company Profile
Genscript Biotech 42 Unlock Company Profile
Gracell Biotechnologies 41 Unlock Company Profile
Editas Medicine 41 Unlock Company Profile
Io Therapeutics 41 Unlock Company Profile
Obsidian Therapeutics 39 Unlock Company Profile
Adicet Bio 35 Unlock Company Profile
Poseida Therapeutics 35 Unlock Company Profile
BioAtla 35 Unlock Company Profile
Puretech Health 34 Unlock Company Profile
Minerva Biotechnologies 34 Unlock Company Profile
Ministry of Trade and Industry, Singapore 33 Unlock Company Profile
IONTAS 33 Unlock Company Profile
Nkarta 32 Unlock Company Profile
Bellicum Pharmaceuticals 31 Unlock Company Profile
CERo Therapeutics 31 Unlock Company Profile
TRON gGmbH 31 Unlock Company Profile

Source: GlobalData Patent Analytics

Bristol-Myers Squibb (BMS) is one of the leading patent filers for genetically modified fusion polypeptides. BMS is a specialty biopharmaceutical company that is engaged in discovery, development, licensing, manufacturing, marketing, distribution, and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic indications.

In terms of application diversity, Jiangsu Hengrui Medicine is the top company, followed by Avectas and Fate Therapeutics. By means of geographic reach, Genscript Biotech holds the top position, while Juventas Cell Therapy and Curocell stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.